VANCOUVER, Oct. 21 /CNW/ - CRH Medical Corporation (CRM:TSX-V) announced
today that during the past few months it has trained over 100
Gastroenterologists as part of its strategic initiative to sell the Company's
patented proprietary hemorrhoid banding technology directly to physicians. The
Company believes this distribution approach complements its core strategy of
operating Centers for Colorectal Health where the CRH technology is
administered. The Company currently operates 17 such Centers across the United
To achieve rapid adoption of the CRH Technology by a broad segment of the
medical community, the Company developed a strategic initiative to sell the
Company's patented proprietary hemorrhoid banding technology, treatment
protocols, marketing and operational experience directly to physicians who see
patients that may be in need of hemorrhoid treatment. By adopting the use of
the CRH Technology, the physician increases practice revenues, expands the
continuum of care and provides a fast, painless and permanent solution to
patients. The Company's initial target for this Program is the approximately
11,000 Gastroenterologists in the U.S. who perform approximately 14 million
colonoscopies each year. The Company estimates that symptomatic hemorrhoids
are diagnosed in 15 - 20% of all colonoscopy patients, most of which go
Commenting on this achievement, Edward Wright CEO of CRH Medical
Corporation stated, "This training milestone demonstrates the substantial
demand for our technology and treatment protocol by Gastroenterologists. The
Gastroenterologists and practices that have been trained are experiencing
significant clinical and financial results. Although the Program is in its
infancy, we are encouraged by the results and look forward to further
expanding this strategy."
Dr. Steve Morris, Managing Partner of Atlanta Gastroenterology Associates
stated "23 of 47 Gastroenterologists in our practice have been trained with
the CRH Technology and treatment protocols. I believe the CRH Technology
provides Atlanta Gastroenterology with the ability to significantly improve
patient outcomes and enhance our profitability."
Dr. Harry Sarles, Finance Committee Chairman, Digestive Health Associates
of Texas states, "The CRH Technology and treatment protocols enable
Gastroenterologists to provide an effective hemorrhoid treatment to the
significant number of patients who are either diagnosed with hemorrhoids
during their colonoscopy or are referred to us complaining of hemorrhoidal
pain and bleeding."
About CRH Medical Corporation:
CRH Medical Corporation is utilizing the first single use, patented,
disposable, hemorrhoid banding system through its Center for Colorectal Health
facilities. According to the National Institute of Health approximately 50% of
the U.S. population will develop hemorrhoids by age 50. CRH Medical is opening
its Center for Colorectal Health facilities in the United States specializing
in the treatment of hemorrhoids, anal fissures, and colon cancer screening and
plans to significantly increase the number of Centers for Colorectal Health
across the U.S. to address this underserved market. The Company's goal is to
become the preeminent resource on colorectal health for consumers and medical
professionals in North America.
About Atlanta Gastroenterology Associates:
Established more than 20 years ago, Atlanta Gastroenterology is the
largest gastroenterology practice in the southeast United States dedicated to
the evaluation and treatment of both digestive and liver diseases. Today, AGA
has more than 45 physicians in 15 locations conveniently located throughout
the metropolitan Atlanta area and in north Georgia.
About Digestive Health Associates of Texas:
One of the largest gastroenterology physician groups in the United
States. With more than 30 locations covering a 100-mile radius, providing
health care services for the Dallas/Fort Worth Metroplex area.
The information in this news release contains so-called "forward-looking"
statements. These include statements regarding CRH Medical expectations,
beliefs, intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we
believe", "CRH Medical believes", "management believes" and similar language.
All forward-looking statements are based on CRH Medical current expectations
and are subject to risks and uncertainties and to assumptions made.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Dean Linden, Corporate Communications, CRH
Medical Corporation at (604) 633-1440 or firstname.lastname@example.org. Additional
information may also be found by visiting the Company's website at
www.crhmedcorp.com or the SEDAR website at www.sedar.com